Santhera gibt den ersten Handelstag der neuen Wandelanleihe an der SIX Swiss Exchange bekannt

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

Pratteln, Schweiz, 7. Mai 2021 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass der Handel der vorrangigen, ungesicherten Wandelanleihe von CHF 30'270'375 mit Fälligkeit 2024 heute an der SIX Swiss Exchange beginnt.

Am 4. Mai 2021 hat die Santhera Pharmaceuticals Holding AG eine vorrangige ungesicherte Wandelanleihe mit Fälligkeit 2024 (die Anleihe 2021/24) im Gesamtnennbetrag von CHF 30'270'375 ausgegeben.

Die Anleihe 2021/24 wurde zum Handel an der SIX Swiss Exchange zugelassen. Der erste Handelstag ist heute, der 7. Mai 2021. Das Tickersymbol der Anleihe 2021/24 lautet SAN21 und die ISIN CH0563348744.

Wie in den Anleihensbedingungen [1] festgelegt, hat die Wandlungsfrist, innert welcher ein Anleihensgläubiger das Wandelrecht für die Anleihe 2021/24 ausüben kann, am 4. Mai 2021 begonnen und endet sieben Handelstage vor dem Fälligkeitstermin am 17. August 2024 (bzw. im Falle einer vorzeitigen Rückzahlung zehn Handelstage vor dem Tag der vorzeitigen Rückzahlung).

Die Anleihensbedingungen [1] sind Teil des Emissions- und Kotierungsprospekts vom 4. Mai 2021, der derzeit von der SIX Exchange Regulation AG als Prüfstelle gemäss Artikel 52 des Schweizerischen Finanzdienstleistungsgesetzes geprüft wird und nach dessen Genehmigung auf der Website von Santhera veröffentlicht wird.

Zugehörige Dokumente
[1] Terms and Conditions (vorbehältlich der Genehmigung durch SIX Exchange Regulation AG): https://www.santhera.de/investors-and-media/investor-toolbox/anleihen

Übersicht ausstehende Santhera Anleihen: https://www.santhera.de/investors-and-media/investor-toolbox/anleihen

Unternehmenskalender
22. Juni 2021        Generalversammlung

Über Santhera
Santhera Pharmaceuticals (SIX: SANN), ein Schweizer Spezialitätenpharmaunternehmen, ist auf die Entwicklung und Vermarktung innovativer Medikamente für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem medizinischem Bedarf fokussiert. Santhera hat eine weltweite Exklusivlizenz für alle Indikationen für Vamorolone, ein first-in-class dissoziatives Steroid mit neuartigem Wirkmechanismus, welches derzeit in einer Zulassungsstudie bei Patienten mit DMD als Alternative zu Standard-Kortikosteroiden getestet wird. Die klinische Pipeline umfasst auch Lonodelestat (POL6014) zur Behandlung von Mukoviszidose (CF) und anderen neutrophilen Lungenerkrankungen und einen explorativen Gentherapieansatz für kongenitale Muskeldystrophien. Santhera hat die Ex-Nordamerika-Rechte an seinem ersten zugelassenen Produkt, Raxone® (Idebenon), zur Behandlung von Leber hereditärer Optikusneuropathie (LHON) an Chiesi Group lizenziert. Weitere Informationen unter www.santhera.com.

Raxone® ist eine eingetragene Marke von Santhera Pharmaceuticals.

Für weitere Auskünfte wenden Sie sich bitte an:
[email protected] oder
Eva Kalias, Head External Communications
Tel.: +41 79 875 27 80
[email protected]

Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

NO ACTION HAS BEEN TAKEN BY SANTHERA PHARMACEUTICALS HOLDING AG (THE COMPANY) OR ANY OF ITS RESPECTIVE AFFILIATES THAT WOULD PERMIT AN OFFERING OF THE 2021/24 BONDS OR POSSESSION OR DISTRIBUTION OF THIS PRESS RELEASE OR ANY OFFERING OR PUBLICITY MATERIAL RELATING TO THE 2021/24 BONDS IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS PRESS RELEASE COMES ARE REQUIRED BY THE COMPANY TO INFORM THEMSELVES ABOUT, AND TO OBSERVE, ANY SUCH RESTRICTIONS.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933 (THE SECURITIES ACT”). THIS PRESS RELEASE IS NOT AN OFFER TO SELL SECURITIES OR THE SOLICITATION OF ANY OFFER TO BUY SECURITIES, NOR SHALL THERE BE ANY OFFER OF SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER OR SALE WOULD BE UNLAWFUL.

THIS PRESS RELEASE AND THE OFFERING WHEN MADE ARE ONLY ADDRESSED TO, AND DIRECTED IN, THE UNITED KINGDOM AND MEMBER STATES OF THE EUROPEAN ECONOMIC AREA (THE EEA) AT PERSONS WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF THE PROSPECTUS REGULATION (QUALIFIED INVESTORS). FOR THESE PURPOSES, THE EXPRESSION PROSPECTUS REGULATION MEANS REGULATION (EU) 2017/1129 AND REGULATION (EU) 2017/1129 AS IT FORMS PART OF UNITED KINGDOM DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (THE EUWA).

THE 2021/24 BONDS ARE NOT INTENDED TO BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO AND SHOULD NOT BE OFFERED, SOLD OR OTHERWISE MADE AVAILABLE TO ANY RETAIL INVESTOR IN THE EEA OR THE UNITED KINGDOM. FOR THESE PURPOSES, A RETAIL INVESTOR MEANS (A) IN THE EEA, A PERSON WHO IS ONE (OR MORE) OF: (I) A RETAIL CLIENT AS DEFINED IN POINT (11) OF ARTICLE 4(1) OF EU DIRECTIVE 2014/65/EU ON MARKETS IN FINANCIAL INSTRUMENTS, AS AMENDED (MIFID II); OR (II) A CUSTOMER WITHIN THE MEANING OF DIRECTIVE (EU) 2016/97, WHERE THAT CUSTOMER WOULD NOT QUALIFY AS A PROFESSIONAL CLIENT AS DEFINED IN POINT (10) OF ARTICLE 4(1) OF MIFID II; OR (III) NOT A QUALIFIED INVESTOR AS DEFINED IN REGULATION (EU) 2017/1129 AND (B) IN THE UNITED KINGDOM, A PERSON WHO IS ONE (OR MORE) OF (I) A RETAIL CLIENT, AS DEFINED IN POINT (8) OF ARTICLE 2 OF REGULATION (EU) NO 2017/565 AS IT FORMS PART OF UNITED KINGDOM DOMESTIC LAW BY VIRTUE OF THE EUWA OR (II) A CUSTOMER WITHIN THE MEANING OF THE PROVISIONS OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 OF THE UNITED KINGDOM (THE FSMA) AND ANY RULES OR REGULATIONS MADE UNDER THE FSMA TO IMPLEMENT DIRECTIVE (EU) 2016/97, WHERE THAT CUSTOMER WOULD NOT QUALIFY AS A PROFESSIONAL CLIENT, AS DEFINED IN POINT (8) OF ARTICLE 2(1) OF REGULATION (EU) NO 600/2014 AS IT FORMS PART OF UNITED KINGDOM DOMESTIC LAW BY VIRTUE OF THE EUWA; OR (III) NOT A QUALIFIED INVESTOR AS DEFINED IN ARTICLE 2 OF THE PROSPECTUS REGULATION.

CONSEQUENTLY, NO KEY INFORMATION DOCUMENT REQUIRED BY REGULATION (EU) NO 1286/2014, AS AMENDED (THE PRIIPS REGULATION) OR THE PRIIPS REGULATION AS IT FORMS PART OF UNITED KINGDOM DOMESTIC LAW BY VIRTUE OF THE EUWA (THE UK PRIIPS REGULATION) FOR OFFERING OR SELLING THE 2021/24 BONDS OR OTHERWISE MAKING THEM AVAILABLE TO RETAIL INVESTORS IN THE EEA OR THE UNITED KINGDOM HAS BEEN PREPARED AND THEREFORE OFFERING OR SELLING THE 2021/24 BONDS OR OTHERWISE MAKING THEM AVAILABLE TO ANY RETAIL INVESTOR IN THE EEA OR THE UNITED KINGDOM MAY BE UNLAWFUL UNDER THE PRIIPS REGULATION AND/OR THE UK PRIIPS REGULATION.

IN ADDITION, IN THE UNITED KINGDOM THIS PRESS RELEASE IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT, QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE ORDER) AND QUALIFIED INVESTORS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (II) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS RELEVANT PERSONS). THIS PRESS RELEASE MUST NOT BE ACTED ON OR RELIED ON (I) IN THE UNITED KINGDOM, BY PERSONS WHO ARE NOT RELEVANT PERSONS, AND (II) IN ANY MEMBER STATE OF THE EEA, BY PERSONS WHO ARE NOT QUALIFIED INVESTORS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS PRESS RELEASE RELATES IS AVAILABLE ONLY TO (A) RELEVANT PERSONS IN THE UNITED KINGDOM AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS IN THE UNITED KINGDOM AND (B) QUALIFIED INVESTORS IN MEMBER STATES OF THE EEA.

THE COMPANY AND ITS RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY STATEMENT CONTAINED IN THIS PRESS RELEASE WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

# # #

 

Anhang

• 2021 05 07_BondFirstTrading_d_final